Switch to: References

Add citations

You must login to add citations.
  1. Fairness and Transparency in an Expanded Access Program: Allocation of the Only Treatment for SMA1.Alyssa M. Burgart, Julie Collier & Mildred K. Cho - 2017 - American Journal of Bioethics 17 (10):71-73.
    Download  
     
    Export citation  
     
    Bookmark  
  • Clinical Research Subject Selection during Public Health Disasters: Reconceptualizing Fairness in a Global Ethical Context.Ikeolu O. Afolabi, Stephen O. Sodeke & Michael O. S. Afolabi - 2020 - American Journal of Bioethics 20 (2):38-41.
    Volume 20, Issue 2, February 2020, Page 38-41.
    Download  
     
    Export citation  
     
    Bookmark  
  • Context is Needed When Assessing Fair Subject Selection.G. Owen Schaefer - 2020 - American Journal of Bioethics 20 (2):20-22.
    Volume 20, Issue 2, February 2020, Page 20-22.
    Download  
     
    Export citation  
     
    Bookmark   1 citation  
  • The Challenge of Selecting Participants Fairly in High-Demand Clinical Trials.Annette Rid, Saskia Hendriks & Alexander A. Iyer - 2020 - American Journal of Bioethics 20 (2):35-38.
    Volume 20, Issue 2, February 2020, Page 35-38.
    Download  
     
    Export citation  
     
    Bookmark  
  • Is There a ‘Right to Try’ Experimental Therapies? Ethical Criteria for Selecting Patients With Spinal Muscular Atrophy to Receive Nusinersen in an Expanded Access Program.Nancy S. Jecker - 2017 - American Journal of Bioethics 17 (10):70-71.
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  • Ethical Guidance for Selecting Clinical Trials to Receive Limited Space in an Immunotherapy Production Facility.Nancy S. Jecker, Aaron G. Wightman, Abby R. Rosenberg & Douglas S. Diekema - 2018 - American Journal of Bioethics 18 (4):58-67.
    Our aims are to set forth a multiprinciple system for selecting among clinical trials competing for limited space in an immunotherapy production facility that supplies products under investigation by scientific investigators; defend this system by appealing to justice principles; and illustrate our proposal by showing how it might be implemented. Our overarching aim is to assist manufacturers of immunotherapeutic products and other potentially breakthrough experimental therapies with the ethical task of prioritizing requests from scientific investigators when production capacity is limited.
    Download  
     
    Export citation  
     
    Bookmark   8 citations  
  • Fairly Allocating Space in an Immunotherapy Production Facility: Reply to Critics.Nancy S. Jecker, Aaron G. Wightman, Abby R. Rosenberg & Douglas S. Diekema - 2018 - American Journal of Bioethics 18 (5):W9-W12.
    Download  
     
    Export citation  
     
    Bookmark  
  • Perverse Effects: How Insufficient Guidance to IPFs Can Undermine Both Research and Health Outcomes of Clinical Trials.John W. Frye - 2018 - American Journal of Bioethics 18 (4):78-80.
    Download  
     
    Export citation  
     
    Bookmark   2 citations